Previous 10 | Next 10 |
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0...
2023-12-12 01:26:03 ET Summary Kinnate Biopharma is focusing on the development of a novel RAF inhibitor to overcome challenges in targeted therapy for melanoma and other BRAF-mutated cancers. The company is narrowing its near-term development to work on the RAF inhibitor exarafen...
2023-11-15 13:30:05 ET Kinnate Biopharma ( KNTE ) +47% . SciSparc ( SPRC ) +46% . Ebix ( EBIX ) +41% . Beauty Health Company ( SKIN ) +35% . Mira Pharmaceuticals ( MIRA ) +38% . Solid Biosciences ( SLDB ) +28% ...
2023-11-15 12:32:14 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cormedix Inc (NASDAQ: CRMD), SciSparc Ltd (NASDAQ: SPRC), Solid Biosciences Inc (NASDAQ: SLDB), Heron ...
Kinnate Biopharma Inc. (NASDAQ: KNTE) is one today's most active stocks by volume. So far today, approximately 75,328 shares of Kinnate Biopharma Inc. have been exchanged, as compared to an average 30-day volume of 115.51k shares. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
2023-11-15 08:45:04 ET SciSparc ( SPRC ) +86% Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation. Kinnate Biopharma ( KNTE ) +41% . Solid Biosciences ( SLDB ) +27% gets FDA okay for clinical testing of DMD gene th...
2023-11-09 17:48:39 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q3 GAAP EPS of -$0.65 beats by $0.04 . As of September 30, 2023, total cash, cash equivalents and investments were $180.3 million, which is expected to fund current operations into at least the se...
Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 select...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...